Figures 5, 6 show group differences between nilvadipine- and placebo-treated mild and moderate AD subjects for CSF Aβ38 (F = 2.98, p = 0.04), total tau (F = 6.29, p < 0.01), and P181 tau (F = 4.30, p < 0.01). Post-hoc analyses showed that in the moderate AD group, nilvadipine treated subjects had significant increases in CSF Aβ38, total tau and P181 tau after nilvadipine treatment (p < 0.05). In addition, YKL-40 and neurogranin significantly differed between moderate AD placebo and nilvadipine treated subjects (Supplementary Figure 3). The gene discussed is MAPT; the disease is Alzheimer disease.